Monitoring of Systemic and Hepatic Hemodynamic Parameters in Mice
October 4th, 2014
16.6K views
This film demonstrates how to acquire systemic and hepatic hemodynamics in mice. The whole monitoring includes acquisition of vital parameters, systemic blood pressure, central venous pressure, common hepatic artery flow rate, and portal vein pressure as well as the portal flow rate in mice.
Overview
This film demonstrates the procedure for monitoring systemic and hepatic hemodynamics in mice. It includes the acquisition of vital parameters such as systemic blood pressure, central venous pressure, and portal vein pressure.
Key Study Components
Area of Science
- Neuroscience
- Physiology
- Hematology
Background
- Understanding hemodynamics is crucial for studying various physiological conditions.
- Monitoring these parameters can provide insights into systemic and hepatic function.
- Utilizing mice as a model organism allows for controlled experimentation.
- Accurate measurement techniques are essential for reliable data.
Purpose of Study
- To demonstrate the methodology for acquiring hemodynamic data in mice.
- To highlight the importance of monitoring vital parameters.
- To provide a comprehensive overview of the necessary equipment and procedures.
Methods Used
- Use of a computer with LabChart software for data acquisition.
- Implementation of a stereo microscope for visualization.
- Utilization of an anesthesia machine for proper animal care.
- Incorporation of a DI system with components like a transit time flow meter.
Main Results
- Successful acquisition of systemic blood pressure and central venous pressure.
- Measurement of common hepatic artery flow rate and portal vein pressure.
- Recording of portal flow rate in mice.
- Demonstration of the effectiveness of the monitoring setup.
Conclusions
- The procedure outlined is effective for monitoring hemodynamics in mice.
- Accurate data acquisition is achievable with the right equipment.
- This methodology can be applied in various research contexts.
Frequently Asked Questions
What equipment is needed for the monitoring procedure?
A computer with LabChart software, a stereo microscope, an anesthesia machine, and a DI system are required.
What parameters are monitored in this procedure?
The procedure monitors systemic blood pressure, central venous pressure, portal vein pressure, and portal flow rate.
Why is it important to monitor hemodynamics?
Monitoring hemodynamics provides insights into physiological conditions and the overall health of the organism.
Can this method be applied to other animal models?
While this method is demonstrated in mice, similar techniques can be adapted for other animal models.
What is the role of the DI system in this procedure?
The DI system is used for precise measurement of blood flow rates and other hemodynamic parameters.
How does the use of anesthesia affect the monitoring?
Anesthesia ensures that the animals remain still and do not experience stress during the monitoring process.
Executive Industry Relevance
Monitoring systemic and hepatic hemodynamics in mice enables precise assessment of liver perfusion and cardiovascular function in preclinical models. This capability supports target validation and mechanistic de-risking by providing quantitative hemodynamic readouts that reflect physiological responses to genetic, pharmacological, or surgical interventions. The procedure enhances predictive confidence in early discovery by allowing direct measurement of portal pressure, flow rates, and vital parameters in disease-relevant systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through direct measurement of portal vein pressure and hepatic artery flow in murine models.
- Operational Value: Provides reproducible hemodynamic phenotyping to clarify pathway involvement in liver physiology and pathophysiology.
- Predictive Value: Supports biological de-risking by detecting small changes in perfusion during interventions like partial hepatectomy or lobe clamping.
Screening & Assay Development
- Assay Readiness: Establishes standardized protocols for quantifying portal flow rate and common hepatic artery flow in mice.
- Quantitative Outputs: Delivers measurable parameters including portal vein pressure (4.4–11.2 cmH₂O) and hepatic artery flow (0.1–0.35 mL/min) for compound screening.
- Platform Reuse: Facilitates scalable hemodynamic assessment across acute and chronic liver injury models.
Translational & Preclinical Research
- Disease Relevance: Models hepatic hemodynamic alterations observed in human pathophysiology, including post-resection pressure changes.
- Translational Continuity: Bridges discovery to preclinical validation by monitoring consistent parameters across normal, resection, and clamping conditions.
- Risk-Adjusted Decisions: Enables detection of perfusion changes that inform go/no-go criteria in liver-directed therapeutic development.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through preclinical assessment by providing hemodynamic phenotyping that informs mechanism-of-action and safety profiling.
- Discovery Biology: Supports hypothesis testing via direct measurement of systemic (CAP, CVP) and hepatic (PVP, portal flow, hepatic artery flow) parameters.
- Screening: Enables assay standardization through reproducible acquisition of vital signs and hemodynamic outputs in murine models.
- Analytics: Generates quantitative readouts (pressure in cmH₂O, flow in mL/min) that allow intergroup comparison and effect size determination.
- Translational Research: Connects to preclinical continuity by demonstrating sensitivity to perfusion changes in resection and clamping models.
- Enterprise Reuse: Represents a reusable capability for hemodynamic assessment across multiple liver injury and pharmacological intervention studies.
Operational & Enterprise Impact
- Scientific Value: Provides predictive confidence in target validation through direct, quantitative assessment of hepatic perfusion and systemic hemodynamics.
- Operational Value: Ensures standardization and reproducibility via calibrated pressure transducers and flow probes with defined baseline procedures.
- Strategic Value: Improves go/no-go decisions by enabling early detection of hemodynamic liabilities in liver-targeted modalities.
- Portfolio Impact: Supports risk-adjusted prioritization by identifying compounds that alter portal pressure or hepatic flow in disease-relevant systems.
Implementation Considerations
- Requires expertise in microvascular surgery and vascular access techniques in murine models.
- Dependent on specialized instrumentation including milli C theater pressure transducers and transonic flow probes (MA 0.5 PSB, MA 1 PSB).
- Necessitates cross-team standardization of calibration procedures (zero and 20 cmH₂O water column) for pressure and flow measurements.
- Involves adaptation considerations across disease models (e.g., normal, hepatectomy, clamping) to maintain signal integrity.
- Practical limitation: procedure duration of ~1.5 hours limits use to acute or terminal experiments due to surgical invasiveness.
Biopharma FAQs
Why does null hypothesis testing matter for portal vein pressure validation?
Null hypothesis testing determines whether observed changes in portal vein pressure after interventions like 70% partial hepatectomy are statistically significant, as demonstrated by the significant increase from 6.87 to 11.41 cmH₂O (P<0.05). This supports target validation by confirming that hemodynamic shifts reflect true biological effects rather than variability.
How does isolating the independent variable (e.g., hepatic artery ligation) fit the discovery pipeline?
Isolating the independent variable, such as ligating the hepatic artery while measuring portal flow, allows researchers to attribute changes in perfusion specifically to that manipulation, supporting mechanistic de-risking in target validation workflows by establishing causal relationships in preclinical models.
What quantitative dependent variable measurements enable compound screening in liver disease models?
Quantitative measurements of portal vein pressure (4.4–11.2 cmH₂O), portal flow rate, and common hepatic artery flow (0.1–0.35 mL/min) serve as dependent variables that enable screening for compounds that modulate hepatic hemodynamics in disease-relevant systems.
Why do replication requirements matter for cross-functional collaboration in hemodynamic studies?
Replication requirements ensure that hemodynamic parameters like carotid artery pressure and central venous pressure are consistent across operators and studies, enabling reliable data sharing between discovery, toxicology, and translational teams for unified go/no-go decisions.
What statistical analysis capabilities are required before implementing hepatic hemodynamic monitoring in preclinical studies?
Implementation requires capability to perform t-tests or ANOVA to compare hemodynamic baselines and post-intervention values (e.g., pre- vs. post-resection portal pressure), ensuring that observed changes in flow or pressure exceed experimental noise and support data-driven advancement decisions.
